EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

被引：2

作者：

Mease, P. J. ^{[1
,2
]}

Deodhar, A. ^{[3
]}

Van der Heijde, D. ^{[4
]}

Behrens, F. ^{[5
]}

Kivitz, A. ^{[6
]}

Lehman, T. ^{[7
]}

Wei, L. ^{[8
]}

Nys, M. ^{[9
]}

Banerjee, S. ^{[10
]}

Nowak, M. ^{[11
]}

机构：

[1] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA

[3] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97201 USA

[4] Leiden Univ, Med Ctr, Rheumatol, Leiden, Netherlands

[5] Goethe Univ, Translat Med & Pharmacol ITMP, CIRI Rheumatol & Fraunhofer Inst, Frankfurt, Germany

[6] Altoona Ctr Clin Res, Dept Rheumatol, Duncansville, PA USA

[7] Bristol Myers Squibb, Rheumatol, Princeton, NJ USA

[8] Bristol Myers Squibb, Med Immunol, Princeton, NJ USA

[9] Bristol Myers Squibb, GBS Biostat, Braine Lalleud, Belgium

[10] Bristol Myers Squibb, Rheumatol & Dermatol, Princeton, NJ USA

[11] Bristol Myers Squibb, Clin R&D, Princeton, NJ USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷

关键词：

D O I：

10.1136/annrheumdis-2021-eular.2653

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0227

引用

页码：137 / 138

页数：2

共 50 条

[31] EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS
Kivitz, Alan
Muensterman, Elena Tomaselli
Kavanaugh, Arthur
van der Heijde, Desiree
Klimiuk, Piotr A.
Valenzuela, Guillermo
Dokoupilova, Eva
Poirier, Gabrielle
Srivastava, Bhaskar
Dasen, Sue
Zhang, Xinyan
Trivedi, Mona
Weng, Haoling Holly
Hong, Ting
Pothula, Peter
Baraliakos, Xenofon
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[32] Cannabidiol Treatment in Hand Osteoarthritis and Psoriatic Arthritis - A Randomized, Double-blind Placebo-controlled Trial
Vela, Jonathan
Kristensen, Salome
Dreyer, Lene
Petersen, Kristian Kjaer
Nielsen, Lars Arendt
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3056 - 3057
[33] Safety of tildrakizumab in psoriatic arthritis: An interim analysis from a randomized, double-blind, placebo-controlled phase 2b trial
Ritchlin, Christopher T.
Strand, Vibeke
Ballerini, Rocco
Chou, Richard
Rozzo, Stephen J.
Mendelsohn, Alan M.
Kavanaugh, Arthur
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB166 - AB166
[34] Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderate-to-severe scalp psoriasis: laboratory parameter results of a Phase 3b/4, multicentre, randomized, double-blind, placebo-controlled trial (PSORIATYK SCALP)
Griffiths, Christopher E. M.
Hoffmann, Matthias
Balagula, Eugene
Napoli, Andrew
Cheng, Chun-Yen
Dyme, Rachel
Hala, Virginia
Pinter, Andreas
Lebwohl, Mark
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[35] Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
Ritchlin, Christopher
Strand, Vibeke
Ballerini, Rocco
Chou, Richard C.
Rozzo, Stephen
Mendelsohn, Alan
Kavanaugh, Arthur
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[36] Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial
Vela, Jonathan
Dreyer, Lene
Petersen, Kristian Kjaer
Arendt-Nielsen, Lars
Duch, Kirsten Skjaerbaek
Kristensen, Salome
PAIN, 2022, 163 (06) : 1206 - 1214
[37] A double-blind placebo-controlled randomized trial of oral saffron in the treatment of rheumatoid arthritis
Sahebari, Maryam
Heidari, Hossein
Nabavi, Shima
Khodashahi, Mandana
Rezaieyazdi, Zahra
Dadgarmoghaddam, Maliheh
Hosseinzaheh, Hossein
Abbasi, Shaghayegh
Hashemzadeh, Kamila
AVICENNA JOURNAL OF PHYTOMEDICINE, 2021, 11 (04) : 332 - 342
[38] Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial
Gottlieb, Alice B.
Armstrong, April W.
Merola, Joseph
Napoli, Andrew
Nowak, Miroslawa
Banerjee, Subhashis
Lehman, Thomas
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2782 - 2785
[39] SAFETY AND EFFICACY OF LY3337641, A BRUTON'S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY
Genovese, Mark C.
Spindler, Alberto
Sagawa, Akira
Park, Won
Dudek, Anna
Kivitz, Alan
Chao, Jeannie
Chan, Lai Shan
Barchuk, William
Nirula, Ajay
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1109 - 1110
[40] Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
Mease, PJ
Gladman, DD
Ritchlin, CT
Ruderman, EM
Steinfeld, SD
Choy, EHS
Sharp, JT
Ory, PA
Perdok, RJ
Weinberg, MA
ARTHRITIS AND RHEUMATISM, 2005, 52 (10): : 3279 - 3289

← 1 2 3 4 5 →